Veltuzumab Biosimilar - Research Grade

Human

CD20

>1mg/ml

Human IgG1 Kappa

Bulk Anti-Human CD20 (2H7) Antibody (ICH1012), Anti-mouse CD20 (18B12) In Vivo Antibody - Low Endotoxin (ICH1277), Rituximab Biosimilar - Research Grade (ICH4011), Obinutuzumab Biosimilar - Research Grade (ICH4026), Ofatumumab Biosimilar - Research Grade (ICH4027), Ublituximab Biosimilar - Research Grade (ICH5297), Ibritumomab Biosimilar - Research Grade (ICH5310), Ocrelizumab Biosimilar - Research Grade (ICH5314), Blontuvetmab Biosimilar - Research Grade (ICH5409), Divozilimab Biosimilar - Research Grade (ICH5483), Epitumomab Biosimilar - Research Grade (ICH5530), Ocaratuzumab Biosimilar - Research Grade (ICH5721), Ripertamab Biosimilar - Research Grade (ICH5826), Tositumomab Biosimilar - Research Grade (ICH5937), Zuberitamab Biosimilar - Research Grade (ICH6012)

https://www.imgt.org/mAb-DB/

ICH3002

P11836

931

RRID:AB_3075735

Blue ice

ICH5099 is a recombinant, unconjugated non-therapeutic analog of veltuzumab, a humanized anti-CD20 IgG1 kappa monoclonal antibody, supplied for research use only. It reproduces the antigen-binding specificity of the originator biologic, which recognizes a conformational epitope on the large extracellular loop of human CD20 (MS4A1, UniProt P11836), and is offered in an unlabeled format free of clinical formulation excipients. As a bench reagent rather than a drug product, it is well suited to controlled experiments: flow-cytometric detection and quantitation of CD20 on B cells, epitope- and affinity-mapping studies, competitive binding versus other anti-CD20 antibodies, and use as a reference or benchmark antibody in ADCC, CDC, and apoptosis assays. It also serves as a positive control and a starting scaffold for ADC and bispecific development work, and for characterizing Fc-effector engineering. The antibody is available at research grade with low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and in bulk milligram-to-gram quantities to support in-vitro assay development and preclinical studies. It is not the clinical drug and is not intended for human or veterinary use. CD20 (MS4A1, UniProt P11836) is a non-glycosylated, four-transmembrane-domain phosphoprotein of the MS4A family, expressed on B lymphocytes from the pre-B through mature and activated stages but absent on hematopoietic stem cells, pro-B cells, and terminally differentiated plasma cells. Its two extracellular loops present a conformational epitope on the larger loop that most therapeutic anti-CD20 antibodies engage. CD20 is not internalized appreciably upon antibody binding and lacks a known natural ligand; it is thought to function as a store-operated calcium channel component and to regulate B-cell activation, proliferation, and cell-cycle progression. Because it is lineage-restricted and stably surface-expressed, CD20 is a validated immunotherapy target, and antibodies against it drive B-cell depletion through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity/phagocytosis, and direct pro-apoptotic signaling.

MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7, membrane spanning 4-domains A1, FMC7

Detects human CD20

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Veltuzumab (anti-CD20) Biosimilar

Q: Is the Veltuzumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Veltuzumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Veltuzumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Veltuzumab that binds human CD20.